Riskified Champions Fraud Prevention as a Leading Partner of International Fraud Awareness Week 2025
17.11.2025 14:00:00 CET | Business Wire | Press Release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, announces its participation in International Fraud Awareness Week, taking place November 16–22, 2025. Joining hundreds of organizations worldwide, Riskified aims to raise awareness about the urgent need to fight fraud and help safeguard merchants and their customers globally, especially as online shopping heats up ahead of the holidays.
Deloitte forecasts holiday ecommerce sales of $305–$311 billion in 2025, bringing a wave of new and returning customers and incremental revenue to businesses. Unfortunately, this growth also presents fraudsters with an enticing opportunity: losses from ecommerce fraud are projected to reach $107 billion by 2029, according to Juniper Research.
AI is reshaping both shopping behavior and criminal tactics at unprecedented speed. Riskified data shows that in Q3 2025, the number of merchants receiving orders from GenAI channels tripled compared to the beginning of the year. In Q3 alone, traffic from GenAI-powered shopping tools was 1.1–1.7 times riskier than typical search traffic. Alongside emerging risks from agentic commerce and AI-driven fraud schemes, this highlights the urgent need for merchants to protect transactions, operations, and customers with advanced strategies and technologies.
“Agents are fundamentally changing the way people shop, enabling greater convenience but also introducing new points of vulnerability,” said Jeff Otto, Chief Marketing Officer at Riskified. “Fraud teams are uniquely positioned to protect both merchants and consumers; they build the guardrails that enable the safe and confident adoption of ecommerce innovation. During the holiday season and beyond, our goal is to ensure all ecommerce channels are sustainable revenue drivers, not vectors for fraud and abuse.”
As an official supporter of International Fraud Awareness Week, Riskified has launched a series of initiatives designed to promote anti-fraud education and vigilance. A centerpiece of our efforts this year is the second annual billboard campaign powered by the New York Stock Exchange. Located in the heart of Times Square in New York City, and, for the first time this year, in Silicon Valley, these billboards spotlight merchants who invest in creating a safe and secure holiday shopping experience for their customers. Visit Riskified.com/FraudWeek for educational content such as “The grinch of ecommerce: Spotting fraud & abuse amidst 2025’s AI-powered holiday shopping,” alongside merchant success stories highlighting effective strategies against fraud.
This initiative is a joint effort between Riskified and its ecommerce ecosystem partners — including AWS, Deloitte, Mastercard, Shopify, Salesforce Commerce Cloud, Fiserv, Checkout.com, and Aurus – aimed at helping consumers make informed decisions when shopping with brands that prioritize fraud protection.
Association of Certified Fraud Examinerspresident John Gill, J.D., CFE, said that the support of organizations around the world helps make International Fraud Awareness Week an effective tool in raising anti-fraud awareness.
“Fraud is an issue that unfortunately affects people from all walks of life around the world and it takes many forms,” said Gill. “Whether it’s a trusted employee stealing from a small business, or organized rings of fraudsters targeting seniors in our community, most people know someone who’s been victimized by fraud. That’s why it’s so important for organizations to join in this fight together to raise awareness during this week and beyond. It is a serious problem that requires a proactive approach toward preventing it and educating people is the first step.”
For more information about increasing awareness and reducing the risk of fraud during International Fraud Awareness Week, visit Riskified.com/FraudWeek.
About Riskified
Riskified (NYSE: RSKD) empowers businesses to unleash ecommerce growth by outsmarting risk. Many of the world’s biggest brands and publicly traded companies selling online rely on Riskified for guaranteed protection against chargebacks, to fight fraud and policy abuse at scale, and to improve customer retention. Developed and managed by the largest team of ecommerce risk analysts, data scientists, and researchers, the Riskified ecommerce risk management platform analyzes the individual behind each interaction to provide real-time decisions and robust identity-based insights. Learn more at www.riskified.com.
About the Association of Certified Fraud Examiners
Based in Austin, Texas, the ACFE is the world's largest anti-fraud organization and premier provider of anti-fraud training and education. Together with more than 95,000 members, the ACFE is reducing business fraud worldwide and inspiring public confidence in the integrity and objectivity within the profession. For more information, visit ACFE.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117150907/en/
Contacts
Corporate Communications:
Cristina Dinozo
Senior Director of Communications
press@riskified.com
Investor Relations:
Chett Mandel
Head of Investor Relations
ir@riskified.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom